Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Reexamination Certificate
2005-03-29
2005-03-29
Leffers, Gerry (Department: 1636)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
C435S006120, C435S007100, C435S235100, C435S320100, C536S023100, C514S002600, C514S04400A, C424S009100
Reexamination Certificate
active
06872519
ABSTRACT:
The present invention relates to compositions and methods for the selection and use of surface exposed epitopes. The present invention includes in vivo and in vitro phage peptide diplay methods for the identification and selection of peptides and peptide associated factors with desired properties (e.g., targeting specificity, stability, etc.). The present invention further provides methods and compositions for the isolation and identification of peptide-specific antibodies. The present invention also includes methods and compositions employing nuclear localization signals for enhanced nuclear transport and expression of DNA.
REFERENCES:
patent: 5811093 (1998-09-01), Merril et al.
Sahu, et al. “Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.” Journal of Immunology, vol. 157, No. 2, pp. 884-891, 1996.*
The 1997 Novagen Catalog, pp. 24-26. Novagen Inc., 601 Science Drive, Madison, WI 53711.*
Arap, W. Et al., “Cancer Treatment By Targeted Drug Delivery to Tumor Vascultature in a Mouse Model.”Science; Jan. 16, 1998; vol. 279; 377-380.
Barinaga, Marcia, “Cancer Research: Peptide-Guided Cancer Drugs Show Promise in Mice.”Science Magazine; Jan. 16, 1998; vol. 279 No. 5349; 323-324.
Bohn, Jorg, “Are Natural Antibodies Involved in Tumour Defence?”Immunology Letters; 1999; vol. 69; 317-320.
Bouvet, Jean-Pierre, Et al., “From Natural Polyreactive Autoauntibodies to A La Carte Monoreactive Antibodies to Infectious Agents: Is It a Small World After All?”Infection and Immunity; Jan. 1998, vol. 66, No. 1; 1-4.
Casali, P. Et al., “Structure and Function of Natural Antibodies.”Current Topics in Microbiology&Immunology; v.210 Pp. 167-179 (1996).
Clackson, Tim, Et al., “Making Antibody Fragments Using Phage Display Libraries.”Nature; Aug. 15, 1991, vol. 352, pp. 624-628.
Dighiero, G., “Natural Autoantibodies, Tolerance, and Autoimmunity.”Annals New York Academy of Sciences; 183-192.
Folkman, Judah, “Addressing Tumor Blood Vessels.”Nature Biotechnology; Jun. 97; vol. 15; 510.
Healy, Kevin E. Et al., “Designing Biomaterials to Direct Biological Responses.”Annals New York Academy of Sciences; pp. 24-35.
Ivanenkov, Vasily, Et al., “Targeted Delivery of Multivalent Phage Display Vectors Into Mammalian Cells.”Biochemica et Biophysica Acta; 1999, vol. 1448; 463-472.
Ivanenkov, Vasily, Et al., “Uptake and Intracellular Fate of Phage Display Vectors in Mammalian Cells.”Biochemica et Biophysica Acta; 1999, vol. 1448; 450-462.
Kassner, Paul D, Et al., “Genetic Selection of Phage Engineered for Receptor-Mediated Gene Transfer to Mammalian Cells.”Biochemical and Biophysical Research Communications; 1999, vol. 264; 921-928.
Koivunen, Erkki Et al., “Tumor Targeting With a Selective Gelatinase Inhibitor.”Nature Biotechnology; Aug. 99; vol. 17; 768-774.
Koivunen, Erkki, Et al., “Identification of Receptor Ligands with Phage Display Peptide Libraries.”The Journal of Nuclear Medicine; May 1999; vol. 40, No. 5; 883-888.
Lacroix-Desmazes, Sebastien, Et al., “Self-Reactive Antibodies (Natural Autoantibodies) in Healthy Individuals.”Journal of Immunological Methods; 1998; vol. 216; 117-137.
McCafferty, John, Et al., “Phage Antibodies: Filamentous Phage Displaying Antibody Variable Domains.”Nature; Dec. 6, 1990; vol. 348; 552-554.
Merril, Carl R. Et al., “Long-Circulating Bacteriophage as Antibacterial Agents.”Proc. Natl. Acad. Sci. USA; Apr. 1996; vol. 93; pp. 3188-3192.
Pasqualini, Renata Et al., “Integrins as Receptors For Tumor Targeting By Circulating Ligands.”Nature Biotechnology; Jun. 97; vol. 15; 542-546.
Pasqualini, Renata, Et al., “Organ Targeting In Vivo Using Phage Display Peptide Libraries.”Nature; Mar. 28, 1996; vol. 380; 364-366.
Rajotte, Daniel, Et al., “Membrane Dipeptidase Is the Receptor for a Lung-Targeting Peptide Identified by In Vivo Phage Display.”The Journal of Biological Chemistry; Apr. 23, 1999; vol. 274, No. 17; 11593-11598.
Rajotte, Daniel, Et al., “Molecular Heterogeneity of the Vascular Endothelium Revealed by In Vivo Phage Display.”J. Clin. Invest.; Jul. 1998; vol. 102, No. 2; 430-437.
Samoylova, Tatiana I. Et al., “Elucidation of Muscle-Binding Peptides by Phage Display Screening.”Muscle&Nerve; Apr. 1999; 460-466.
Sokoloff Alexander V.
Wolff Jon A.
Johnson Mark K.
Leffers Gerry
Mirus Bio Corporation
LandOfFree
In vitro process for selecting phage resistant to blood... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with In vitro process for selecting phage resistant to blood..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and In vitro process for selecting phage resistant to blood... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3403004